Therapy of Type 2 Diabetes

Cites (245)

Items 201–245 of 245

1. Addition of or switch to insulin therapy in people treated with glucagon‐like peptide‐1 receptor agonists: A real‐world study in 66 583 patients
   Olga Montvida, Kerenaftali Klein, Sudhesh Kumar, Kamlesh K. Khunti, Sanjoy Ketan Paul · 2016 · Diabetes Obesity and Metabolism
2. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
   Philip Home, Bo Åhrén, Jane E.B. Reusch, Marc Rendell, Peter N. Weissman, Deborah T. Cirkel, Diane M. Miller, Phil Ambery, Molly C. Carr, Michael Albrecht Nauck · 2017 · Diabetes Research and Clinical Practice
3. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
   Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria‐Inti Metzendorf, Bernd Richter, Bianca Hemmingsen · 2019 · Cochrane Database of Systematic Reviews
4. Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: A systematic review and meta-analysis
   Guillem Jabardo-Camprubí, Rafel Donat Roca, Mercè Sitjà‐Rabert, Raimón Milà, Judit Bort Roig · 2019 · Physiology & Behavior
5. Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials
   Kang Chen, Deying Kang, Miao Yu, Ruya Zhang, Ye Zhang, Guojuan Chen, Yiming Mu · 2017 · Diabetes Obesity and Metabolism
6. Weight change 2 years after termination of the intensive lifestyle intervention in the Look AHEAD study.
   Look AHEAD Research Group, Chao, Ariana M., Wadden, Thomas A., Berkowitz, Robert I., Blackburn, George, Bolin, Paula, Clark, Jeanne M., Coday, Mace, Curtis, Jeffrey M., Delahanty, Linda M. et al. · 2020 · Obesity
7. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
   Xiaodong Zhuang, Xin He, Da-Ya David Yang, Yue Guo, Jiangui He, Haipeng Xiao, Xinxue Liao · 2018 · Cardiovascular Diabetology
8. Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
   W. Ryan Powell, C L Christiansen, Donald R. Miller · 2018 · Diabetes Therapy
9. Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
   Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, Maciej Błażej Hajduga, Jan Bujok, Celina Pająk, Michał Ćwiertnia · 2020 · Heart Failure Reviews
10. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
    Dagenais, Gilles R., Rydén, Lars, Leiter, Lawrence A., Lakshmanan, Mark, Dyal, Leanne, Probstfield, Jeffrey L., Atisso, Charles Messan, Shaw, Jonathan E., Conget, Ignacio, Cushman, William C. et al. · 2020 · Cardiovascular Diabetology
11. Definition, Klassifikation und Diagnostik des Diabetes mellitus: Update 2020
    Matthias A. Nauck, Christian Gerdes, Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Guido Freckmann, Lutz Heinemann, Erwin D. Schleicher, Rüdiger Landgraf · 2020 · Diabetologie und Stoffwechsel
12. The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose–response of randomized clinical trials
    Jamal Rahmani, Nicla Manzari, Jacqueline Thompson, Sai Krishna Gudi, Manik Chhabra, Gurudatta Naik, Seyed Mohammad Mousavi, H. K. Varkaneh, Cain C. T. Clark, Y. Zhang · 2019 · Clinical & Translational Oncology
13. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
    Steven P. Marso, Michael Albrecht Nauck, Tea Monk Fries, Søren Rasmussen, Marianne Bach Treppendahl, John B. Buse · 2018 · The American Journal of Cardiology
14. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
    Jeff Y. Yang, Tiansheng Wang, Virginia Pate, John B. Buse, Til Stürmer‎ · 2020 · BMJ Open Diabetes Research & Care
15. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
    Jennifer K. Leohr, Mary Anne Dellva, David E. Coutant, Elizabeth Smith LaBell, Tim Heise, Grit Andersen, Eric Zijlstra, Lidia Hermanski, Leszek Nosek, Helle Linnebjerg · 2020 · Clinical Pharmacokinetics
16. The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
    Hengzhi Du, Dao Wen Wang, Chen Chen · 2020 · Journal of Cellular and Molecular Medicine
17. Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
    Ip Tim Lau, Ka Fai Lee, Wing Yee So, K. C. B. Tan, Ming Wai Yeung · 2017 · Diabetes Metabolic Syndrome and Obesity
18. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
    Ueda, Peter, Wintzell, Viktor, Melbye, Mads, Eliasson, Björn, Svensson, Ann-Marie, Franzén, Stefan, Gudbjörnsdottir, Soffia, Hveem, Kristian, Jonasson, Christian, Svanström, Henrik et al. · 2021 · Diabetologia
19. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review
    Shishi Xu, Xinyue Zhang, Lizhi Tang, Fang Zhang, Nanwei Tong · 2016 · Postgraduate Medicine
20. Biosimilar vs originator insulins: Systematic review and meta‐analysis
    Tomohide Yamada, Ryuichi Kamata, Kotomi Ishinohachi, Nobuhiro Shojima, Sophia Ananiadou, Hisashi Nom, Toshimasa Yamauchi, Takashi Kadowaki · 2018 · Diabetes Obesity and Metabolism
21. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis
    Basem M. Mishriky, Doyle M. Cummings, J.R. Powell, Kerry B. Sewell, Robert J. Tanenberg · 2018 · Diabetes & Metabolism
22. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis
    Wenqin Guo, Lang Li, Qiang Su, Weiran Dai, Ziliang Ye · 2017 · Value in Health
23. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials
    Bo Åhrén, Molly C. Carr, Karen Murphy, Christopher Perkins, Marc Rendell, Jason M. Mallory, Timothy H. Wilson, SUSAN L. JOHNSON · 2017 · Diabetes Research and Clinical Practice
24. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim · 2021 · Endocrinology and Metabolism
25. A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U-100 versus concentrated lispro insulin U-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence
    Gentile, Sandro, Fusco, Alessandra, Colarusso, Sara, Piscopo, Marco, Improta, Maria Rosaria, Corigliano, Marco, Martedi, Emilia, Oliva, Domenica, Santorelli, Antonietta, Simonetti, Rosa et al. · 2018 · Expert Opinion on Drug Safety
26. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes
    Oyepeju Ogundipe, Mohsen Mazidi, Ken Lee Chin, Deval Gor, Andrew Peter McGovern, Berhe Weldearegawi Sahle, György Jermendy, Maarit Jaana Korhonen, Bernard Appiah, Zanfina Ademi et al. · 2020 · Acta Diabetologica
27. Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen?
    Rüdiger Landgraf, Matthias A. Nauck, Guido Freckmann, Ulrich Müller, Lutz Heinemann, Monika Kellerer, Dirk Müller‐Wieland · 2018 · DMW - Deutsche Medizinische Wochenschrift
28. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes
    Mei Qiu, Liang‐Liang Ding, Hairong Zhou · 2021 · Medicine
29. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
    Guangyao Li, Matthew J. Crowley, Huilin Tang, Jeff Y. Yang, Robert S. Sandler, Tiansheng Wang · 2019 · Diabetes Care
30. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close
    Theocharis Koufakis, Omar G. Mustafa, Pantelis E Zebekakis, Kalliopi Kotsa · 2020 · Diabetic Medicine
31. HbA1c in der Diabetesdiagnostik
    Rüdiger Landgraf · 2021 · Diabetes aktuell
32. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial
    Jie Yu, Jingwei Li, Phillip J Leaver, Clare Gabrielle Arnott, Mark D. Huffman, Jacob Allen Udell, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher et al. · 2021 · Cardiovascular Research
33. Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
    Philip D. Home, Lawrence Blonde, Sanjay Kalra, Linong Ji, Patricia Guyot, Claire Brulle-Wohlhueter, Erin M. Murray, Roshan Shah, Toby Sayre, Alka Shaunik · 2020 · Diabetes Obesity and Metabolism
34. HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose?
    Lutz Heinemann, Patricia Kaiser, Guido Freckmann, Denis Grote-Koska, W. Kerner, Rüdiger Landgraf, Ludwig Merker, Ulrich Müller, Dirk Müller‐Wieland, Johannes Roth et al. · 2018 · Diabetologie und Stoffwechsel
35. Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
    Riccardo C. Bonadonna, Éric Renard, ALICE Y.Y. CHENG, Andreas Fritsche, Anna M. G. Cali, Lydie Melas‐Melt, Guillermo E. Umpierrez · 2018 · Diabetes Research and Clinical Practice
36. Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin
    Naveed A. Sattar, Darren K. McGuire · 2020 · European Heart Journal
37. Evidenz in der Ernährungstherapie des Diabetes mellitus
    Hans Hauner · 2021 · Der Diabetologe
38. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini · 2019 · Acta Diabetologica
39. Metformin: still the sweet spot for CV protection in diabetes?
    Graham Rena, Ify R. Mordi, Chim Choy Lang · 2020 · Current Opinion in Pharmacology
40. Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
    Richard J. MacIsaac · 2020 · Diabetes Therapy
41. Lipidtherapie bei Patienten mit Diabetes mellitus
    Klaus Georg Parhofer, Andreas L. Birkenfeld, Wilhelm Krone, Michael Lehrke, Nikolaus Marx, Martin Merkel, Katharina S. Schütt, Andreas Zirlik, Dirk Müller‐Wieland · 2021 · Der Diabetologe
42. Diabetes, Sport und Bewegung
    Katrin Esefeld, Stephan Kreß, Meinolf Behrens, Peter Zimmer, Michael Stümvoll, Ulrike Thurm, Bernhard Gehr, Christian Karl Brinkmann, Martin Halle · 2021 · Diabetologie und Stoffwechsel
43. Adipositas und Diabetes
    Jens Aberle, Anne Lautenbach, Svenja Meyhöfer, Sebastian M. Meyhöfer, Lars Selig, Matthias Blüher, Markus Menzen · 2021 · Diabetologie und Stoffwechsel
44. Lipidtherapie bei Patienten mit Diabetes mellitus
    Klaus Georg Parhofer, Andreas L. Birkenfeld, Wilhelm Krone, Michael Lehrke, Nikolaus Marx, Martin Merkel, Katharina S. Schütt, Andreas Zirlik, Dirk Müller‐Wieland · 2023 · Die Diabetologie
45. Hundert Jahre – Insulin bleibt aktuell und notwendig
    Rüdiger Landgraf, Jens Aberle · 2021 · Diabetologie und Stoffwechsel